Cargando…

In vitro synergy between sodium deoxycholate and furazolidone against enterobacteria

BACKGROUND: Antimicrobial combinations have been proven as a promising approach in the confrontation with multi-drug resistant bacterial pathogens. In the present study, we identify and characterize a synergistic interaction of broad-spectrum nitroreductase-activated prodrugs 5-nitrofurans, with a s...

Descripción completa

Detalles Bibliográficos
Autores principales: Le, Vuong Van Hung, Olivera, Catrina, Spagnuolo, Julian, Davies, Ieuan G., Rakonjac, Jasna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6945529/
https://www.ncbi.nlm.nih.gov/pubmed/31906851
http://dx.doi.org/10.1186/s12866-019-1668-3
_version_ 1783485195774590976
author Le, Vuong Van Hung
Olivera, Catrina
Spagnuolo, Julian
Davies, Ieuan G.
Rakonjac, Jasna
author_facet Le, Vuong Van Hung
Olivera, Catrina
Spagnuolo, Julian
Davies, Ieuan G.
Rakonjac, Jasna
author_sort Le, Vuong Van Hung
collection PubMed
description BACKGROUND: Antimicrobial combinations have been proven as a promising approach in the confrontation with multi-drug resistant bacterial pathogens. In the present study, we identify and characterize a synergistic interaction of broad-spectrum nitroreductase-activated prodrugs 5-nitrofurans, with a secondary bile salt, sodium deoxycholate (DOC) in growth inhibition and killing of enterobacteria. RESULTS: Using checkerboard assay, we show that combination of nitrofuran furazolidone (FZ) and DOC generates a profound synergistic effect on growth inhibition in several enterobacterial species including Escherichia coli, Salmonella enterica, Citrobacter gillenii and Klebsiella pneumoniae. The Fractional Inhibitory Concentration Index (FICI) for DOC-FZ synergy ranges from 0.125 to 0.35 that remains unchanged in an ampicillin-resistant E. coli strain containing a β-lactamase-producing plasmid. Findings from the time-kill assay further highlight the synergy with respect to bacterial killing in E. coli and Salmonella. We further characterize the mechanism of synergy in E. coli K12, showing that disruption of the tolC or acrA genes that encode components of multidrug efflux pumps causes, respectively, a complete or partial loss, of the DOC-FZ synergy. This finding indicates the key role of TolC-associated efflux pumps in the DOC-FZ synergy. Overexpression of nitric oxide-detoxifying enzyme Hmp results in a three-fold increase in FICI for DOC-FZ interaction, suggesting a role of nitric oxide in the synergy. We further demonstrate that DOC-FZ synergy is largely independent of NfsA and NfsB, the two major activation enzymes of the nitrofuran prodrugs. CONCLUSIONS: This study is to our knowledge the first report of nitrofuran-deoxycholate synergy against Gram-negative bacteria, offering potential applications in antimicrobial therapeutics. The mechanism of DOC-FZ synergy involves FZ-mediated inhibition of TolC-associated efflux pumps that normally remove DOC from bacterial cells. One possible route contributing to that effect is via FZ-mediated nitric oxide production.
format Online
Article
Text
id pubmed-6945529
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-69455292020-01-07 In vitro synergy between sodium deoxycholate and furazolidone against enterobacteria Le, Vuong Van Hung Olivera, Catrina Spagnuolo, Julian Davies, Ieuan G. Rakonjac, Jasna BMC Microbiol Research Article BACKGROUND: Antimicrobial combinations have been proven as a promising approach in the confrontation with multi-drug resistant bacterial pathogens. In the present study, we identify and characterize a synergistic interaction of broad-spectrum nitroreductase-activated prodrugs 5-nitrofurans, with a secondary bile salt, sodium deoxycholate (DOC) in growth inhibition and killing of enterobacteria. RESULTS: Using checkerboard assay, we show that combination of nitrofuran furazolidone (FZ) and DOC generates a profound synergistic effect on growth inhibition in several enterobacterial species including Escherichia coli, Salmonella enterica, Citrobacter gillenii and Klebsiella pneumoniae. The Fractional Inhibitory Concentration Index (FICI) for DOC-FZ synergy ranges from 0.125 to 0.35 that remains unchanged in an ampicillin-resistant E. coli strain containing a β-lactamase-producing plasmid. Findings from the time-kill assay further highlight the synergy with respect to bacterial killing in E. coli and Salmonella. We further characterize the mechanism of synergy in E. coli K12, showing that disruption of the tolC or acrA genes that encode components of multidrug efflux pumps causes, respectively, a complete or partial loss, of the DOC-FZ synergy. This finding indicates the key role of TolC-associated efflux pumps in the DOC-FZ synergy. Overexpression of nitric oxide-detoxifying enzyme Hmp results in a three-fold increase in FICI for DOC-FZ interaction, suggesting a role of nitric oxide in the synergy. We further demonstrate that DOC-FZ synergy is largely independent of NfsA and NfsB, the two major activation enzymes of the nitrofuran prodrugs. CONCLUSIONS: This study is to our knowledge the first report of nitrofuran-deoxycholate synergy against Gram-negative bacteria, offering potential applications in antimicrobial therapeutics. The mechanism of DOC-FZ synergy involves FZ-mediated inhibition of TolC-associated efflux pumps that normally remove DOC from bacterial cells. One possible route contributing to that effect is via FZ-mediated nitric oxide production. BioMed Central 2020-01-06 /pmc/articles/PMC6945529/ /pubmed/31906851 http://dx.doi.org/10.1186/s12866-019-1668-3 Text en © The Author(s). 2020 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Le, Vuong Van Hung
Olivera, Catrina
Spagnuolo, Julian
Davies, Ieuan G.
Rakonjac, Jasna
In vitro synergy between sodium deoxycholate and furazolidone against enterobacteria
title In vitro synergy between sodium deoxycholate and furazolidone against enterobacteria
title_full In vitro synergy between sodium deoxycholate and furazolidone against enterobacteria
title_fullStr In vitro synergy between sodium deoxycholate and furazolidone against enterobacteria
title_full_unstemmed In vitro synergy between sodium deoxycholate and furazolidone against enterobacteria
title_short In vitro synergy between sodium deoxycholate and furazolidone against enterobacteria
title_sort in vitro synergy between sodium deoxycholate and furazolidone against enterobacteria
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6945529/
https://www.ncbi.nlm.nih.gov/pubmed/31906851
http://dx.doi.org/10.1186/s12866-019-1668-3
work_keys_str_mv AT levuongvanhung invitrosynergybetweensodiumdeoxycholateandfurazolidoneagainstenterobacteria
AT oliveracatrina invitrosynergybetweensodiumdeoxycholateandfurazolidoneagainstenterobacteria
AT spagnuolojulian invitrosynergybetweensodiumdeoxycholateandfurazolidoneagainstenterobacteria
AT daviesieuang invitrosynergybetweensodiumdeoxycholateandfurazolidoneagainstenterobacteria
AT rakonjacjasna invitrosynergybetweensodiumdeoxycholateandfurazolidoneagainstenterobacteria